However, this approach disrupts a self-sustaining vicious cycle, reduces mortality and is now well-established as one of the first line therapies of this disease.53 Similarly, anti-FGF23-based therapies may prove useful in the treatment of CKD despite their potential phosphate-retaining effects. The gene discussed is FGF23; the disease is chronic kidney disease.